Ertapenem

Generic name
Ertapenem
Brand name
ATC Code
J01DH03
Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

  3 months-12 years 13-17 years
Vd 0,2 l/kg 0,16 l/kg
T½ 2,5 hours 4 hours
Cmax 3-23 months: 103,8 microg/ml
2-12 years: 113,2 microg/ml		 170,4 microg/ml

Source: SmpC Invanz

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Bacterial infections
  • Intravenous
    • 3 months up to 13 years
      • 30 mg/kg/day in 2 doses. Max: 1 g/day.
    • 13 years up to 18 years
      • 1 g/day in 1 dose

Renal impaiment in children > 3 months

Adjustment in renal impairment as specified:

GFR 50-80 ml/min/1.73 m2
No dose adjustment needed
GFR 30-50 ml/min/1.73 m2
No dose adjustment needed
GFR 10-30 ml/min/1.73 m2
First dose: no dose adjustment, following dosis: 50% of normal single dose
GFR < 10 ml/min/1.73 m2
Avoid use.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Common (1-10%): diarrhea. Diaper dermatitis. Pain at the infusion site. Increase in liver enzyme levels. Decrease in neutrophil count.

Uncommon (0.1-1%): hypertension, hot flashes. Headache. Discoloration of feces, melena. Skin rash, erythema, petechiae. Burning sensation, itching or erythema at the infusion site. Decrease in hemoglobin concentration. Increase in platelet count, increase in prothrombin time and aPTT.

Furthermore, hallucination, altered mental states (such as aggression) have been reported.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

OTHER BETA-LACTAM ANTIBACTERIALS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

First-generation cephalosporins
J01DB05
J01DB04
J01DB01
J01DB03
Second-generation cephalosporins
J01DC04
J01DC03
J01DC02
Third-generation cephalosporins
J01DD08
J01DD01
J01DD13
J01DD52
J01DD02
J01DD14
J01DD04
Fourth-generation cephalosporins
J01DE01
Monobactams
J01DF01
Carbapenems
J01DH51
J01DH02
MONOBACTAMS
J01DF01
Other cephalosporins and penems
J01DI02

Reference

  1. Merck Sharp & Dohme B.V., SmPC Invanz (EU/1/02/216) Rev 26; 25-10-2022, www.ema.europa.eu

Changes

Therapeutic Drug Monitoring


Overdose